[ad_1]
ABU DHABI, 12th May, 2023 (GLOBE NEWSWIRE) — Insilico Medicine, a drug discovery company driven by generative artificial intelligence (AI), announces that it is launching Disease Modeling and Target Recognition Courses, available free of charge. Through seven lectures, the course guides participants through the latest insights into disease modeling and target discovery—key areas of biomedical research that involve the use of computational and experimental methods to gain insight into the causes of disease and identify potential targets for drug development.
The course uses case studies to illustrate the practical application of the concepts covered. In particular, learners will have the opportunity to explore a demo version of PandaOmics, Insilico Medicine’s generative AI tool for target discovery, developed by a team of scientists at Insilico Medicine’s Generative Artificial Intelligence and Quantum Computing R&D Center in Abu Dhabi, which The largest artificial intelligence biotechnology research center in the region.
PandaOmics is used by numerous pharmaceutical companies and has developed 31 drug assets in progress in Insilico’s own pipeline — including two drugs currently in clinical trials for idiopathic pulmonary fibrosis and COVID-19.
Upon completion of the course, participants will receive: .
- Gain insight into the challenges and opportunities of drug target discovery, including the emerging role of artificial intelligence, recent achievements and failures of pharmaceutical companies, and the most promising therapeutic areas;
- Practical skills in identifying and evaluating potential drug targets, including familiarity with several popular tools and resources;
- Learn about the latest trends and emerging topics in target discovery, such as the use of large language models and the evolution of pharmacogenomic concepts;
- Exposure to several case studies illustrating the practical application of the concepts covered, as well as the ability to critically evaluate and compare different target discovery strategies.
The course is open to anyone interested in drug discovery, biomedical research and healthcare innovation, including researchers, scientists, pharmaceutical professionals and students pursuing degrees in molecular biology, chemistry or related fields who wish to understand how fundamental science can be applied for the development of new therapies.
Dr Alex Zhavoronkov, Founder and CEO of Insilico Medicine, said: “This course is aligned with our larger mission to accelerate the development of new treatments by making technological breakthroughs accessible to all scientists, including students who may be interested in pursuing AI drug discovery. Discovery and development.” , who is one of the course instructors.
Insilico has previously supported young researchers using its platform.Three high school researchers use PandaOmics to discover new targets in glioblastoma and aging, results recently Published in the journal Aging. And Insilico has always been a supporter of the Youth Longevity Association, sponsoring young scientists to participate in the Aging Research and Drug Discovery Conference In Copenhagen, it was a signature event co-sponsored by Zhavoronkov.
About Insilico Medicine
Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, is using next-generation AI systems to bridge biology, chemistry, and clinical trial analysis. The company has developed an artificial intelligence platform that utilizes deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover new targets and generate new molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative medicines for cancer, fibrosis, immunity, central nervous system disorders, infectious diseases, autoimmune diseases and age-related diseases. In early 2023, the company opened the Insilico Medicine Generative Artificial Intelligence and Quantum Computing R&D Center in Abu Dhabi, the largest AI biotechnology research center in the region. The R&D center brings together global talent in AI and software development to expand the capabilities of Insilico’s end-to-end AI-driven drug discovery platform, Pharma.AI, explore aging research and sustainable chemistry, and support digital transformation in healthcare the area.
For more information, please visit www.insilico.com
- Insilico Medicine’s Disease Modeling and Target Identification Course
- Course covers topics in AI object discovery
[ad_2]
Source link